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Background: Hyperuricemia may contribute to renal injury. We do not know whether use of treatments that lower
urate reduce the progression of chronic kidney disease (CKD) and cardiovascular disease. We performed a systematic
review and meta-analysis of randomized controlled trials to assess the benefits and risks of treatments that lower urate
in patients with stages 3-5 CKD.
Methods: We searched MEDLINE, EMBASE, CENTRAL, Web of Science and trial registers for randomized controlled trials
(RCTs) without language restriction. Two authors independently screened articles, assessed risk of bias and extracted
data. Data obtained included serum uric acid, serum creatinine or other estimates of glomerular filtration rate,
incidence of end-stage renal disease (ESRD), systolic and diastolic blood pressure, proteinuria, cardiovascular disease
and adverse events.
Results: From the 5497 citations screened, 19 RCTs enrolling 992 participants met our inclusion criteria. Given
significant heterogeneity in duration of follow-up and study comparators, only trials greater than 3 months comparing
allopurinol and inactive control were meta-analyzed using random effects models. Pooled estimate for eGFR was in
favour of allopurinol with a mean difference (MD) of 3.2 ml/min/1.73 m2, 95% CI 0.16-6.2 ml/min/1.73 m2, p = 0.039 and
this was consistent with results for serum creatinine. Statistically significant reductions in serum uric acid, systolic and
diastolic blood pressure were found, favouring allopurinol. There were insufficient data on adverse events, incidence of
ESRD and cardiovascular disease for analysis.
Conclusions: Adequately powered RCTs are needed to establish whether treatments that lower urate have beneficial
renal and cardiovascular effects.
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The prevalence of recognized chronic kidney disease
(CKD) is increasing globally [1]. Patients with CKD have
higher mortality rates and reduced quality of life relative
to the general population [2]. They are also at a dispro-
portionally higher cardiovascular risk, and most patients
with CKD die of cardiovascular disease (CVD) rather
than progress to end-stage renal disease (ESRD) [3]. The
importance of finding modifiable risk factors that slow* Correspondence: tahir.kanji@medportal.ca
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be understated.
Because low glomerular filtration rate (GFR) leads to
hyperuricemia, CKD is associated with hyperuricemia
and gout [4]. Hyperuricemia has also consistently been
associated with incident CKD, though its association
with progression of CKD has been less clear [5-27].
Currently, urate-lowering therapy (ULT) is only used
for patients with clinical evidence of crystal deposition
such as gout or urolithiasis [28]: routine prophylaxis of
asymptomatic hyperuricemia is not recommended in
current guidelines. This systematic review summarizes
evidence from randomized controlled trials that examinedhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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renal and cardiovascular outcomes.
Methods
Study selection
We included studies if their selection criteria specified
estimated glomerular filtration rate (eGFR) <60 ml/min/
1.73 m2 or their baseline mean eGFR or serum creatin-
ine were <60 ml/min/1.73 m2 or >137 μmol/L for men,
and >104 μmol/L for women, respectively (>1.55 mg/dL
for men and >1.18 mg/dL for women) [29]. Any phar-
macologic therapy given to lower uric acid was consid-
ered a suitable intervention. These included allopurinol,
febuxostat, probenecid, sulfinpyrazone, benzbromarone,
pegloticase and rasburicase. We included studies in
which the comparator was placebo, usual therapy or an
alternative drug. Outcomes of greatest interest were: se-
rum creatinine level, eGFR, proteinuria, incidence of
ESRD, incidence of cardiovascular events and cardiovas-
cular mortality. Other outcomes were: serum uric acid
level, blood pressure (diastolic and systolic), markers of
inflammation (C-reactive protein levels), all-cause mor-
tality, adverse events and serious adverse events. We
included only RCTs and quasi-RCTs. We accepted any
estimate of GFR, whether derived from serum creatinine
and demographic variables, or from directly-measured
creatinine or isotope clearance. We followed a prespeci-
fied protocol but this was not registered.
Finding relevant studies
In the primary search, citations were compiled from the
following electronic databases: Ovid MEDLINE (1966-
June 2013), Ovid EMBASE (1980-June 2013), CENTRAL
(June 2013) and Web of Science (June 2013) using
search strategies detailed in the Additional file 1. We
reviewed the Cochrane Collaboration’s protocol and
adapted some of their search terms [30]. The first arm
of our search strategy included terms such as: kidney
disease, renal insufficiency and renal replacement ther-
apy as well as further synonyms and key words. These
were combined with the second arm of our strategy
comprising of terms such as allopurinol, gout suppres-
sants, urate oxidase and further descriptors related to
ULT. The citations were downloaded into Endnote, ver-
sion X7 (Thompson ISI Research-Soft, Philadelphia, PA)
and duplicate citations removed.
To further identify relevant studies, a secondary search
was performed, making use of reference lists of previous
narrative reviews [31-33] and of studies identified in the
primary search, PubMed ‘Related Articles’ feature, pub-
lished abstracts from two recent American Society of
Nephrology (2010-2012) and International Society of
Nephrology meetings (2010-2012), internet searches using
Google Scholar, and trial registers from National Instituteof Health and Current Controlled Trials. We also identi-
fied seven studies [34-40] from two recently published sys-
tematic reviews on a similar question [41,42].
Two authors (TK, MG) completed the first phase of
screening using titles and abstracts (kappa of 0.84).
Agreement for the second phase of screening, using full-
text manuscripts, was lower at a kappa of 0.41. All dis-
agreements for both phases were resolved by consensus.
Data abstraction and quality assessment
Two authors (TK and MG) independently extracted data
for each included study using standardized forms. Subse-
quently, quality assessment was also completed in dupli-
cate (TK, MG) using the Cochrane Collaboration’s
Higgins Risk of Bias Assessment Tool [43]. Disagree-
ments from both data abstraction and quality assessment
were resolved through consensus. All the non-English
language studies were written in Chinese; data was ex-
tracted and quality assessed by one author (TK), with
the assistance of a translator.
Data synthesis and meta-analysis
Given the heterogeneity in duration of follow up and
study comparators, we decided to meta-analyze studies
greater than 3 months in duration that compared allo-
purinol to inactive control [34,36-40,44-48].
We used a random-effects model within Comprehen-
sive Meta-analysis (Englewood NJ). Two of the studies
did not report GFR estimates [46,48]: we used serum
creatinine and demographic information from the stud-
ies, to estimate mean eGFR. The equations utilized were
Modification of Diet in Renal Disease (MDRD) with
Chinese coefficients where appropriate [49].
Results
Primary electronic database searches identified 5994 ci-
tations, which was reduced to 5497 citations by dedupli-
cation. We retrieved 32 full-text manuscripts from the
electronic search and a further eight from secondary
sources, of which 19 studies were relevant (Figure 1).
Description of studies
The 19 studies, published between 1998 and 2012, ran-
domized 992 participants with duration of follow-up
ranging from 2 days to 24 months; 16 were parallel
group and 3 were crossover design (Table 1). The studies
originated from 10 different countries, including the
United States, United Kingdom, Iran, France, Italy,
Greece, Spain and China. Most were single-centre and
had relatively small sample sizes with short duration of
follow up. Populations were variable and half the studies
did not report usage of baseline renin-angiotensin-
aldosterone system (RAAS) blockade (Table 2).
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Figure 1 Flow diagram.
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Pooled estimate of eGFR was in favour of allopurinol
with a mean difference (MD) of 3.2 ml/min/1.73 m2,
95% confidence interval (CI) 0.16-6.2 ml/min/1.73 m2,
p = 0.039. Heterogeneity was measured with a Q-value
of 6.95 and I2 of 42.5, p = 0.138. We performed a sensi-
tivity analysis excluding studies in which we had calcu-
lated eGFR from serum creatinine: in this analysis, the
tendency was in the same direction but the results did
not meet formal statistical significance. Pooling of se-
rum creatinine also favoured allopurinol with a mean
difference of 0.63 mg/dL, 95% CI 0.43-0.83 mg/dL. As
expected, a statistically significant reduction in serum
uric acid was found with a MD of 2.8 mg/dL, 95% CI
2.3-3.4 mg/dL, p < 0.001. Notably reductions were
found for both pooled estimates of systolic (MD
6.6 mmHg, 95% CI 2.0-11.1 mmHg) and diastolic blood
pressure (MD 2.1 mmHg, 95% CI 0.50-3.7 mmHg). Pro-
teinuria showed a tendency towards benefit, again favour-
ing allopurinol (Figure 2). A funnel plot was completed
for serum creatinine, which showed mild asymmetry con-
sistent with publication bias (Figure 3).
We did not meta-analyze trials of less than three
months’ duration, because we thought it biologically im-
plausible that effects would be observable so rapidly.
Three trials with less than one month of follow up did
not show statistically significant differences in renalfunction [50-53]. There were three studies of between
one and three months’ duration: uricosuric amlodipine
compared to tertatolol showed higher eGFR in the group
treated with amlodipine [54]; creatinine clearance im-
proved following a single dose infusion of rasburicase
compared to placebo [55]; and there was a tendency to-
wards higher eGFR in a comparison of benzbromarone
to allopurinol [56].
There were insufficient data on adverse events, inci-
dence of ESRD and cardiovascular events for meta-
analysis. One study reported cardiovascular event rates
finding a statistically significant reduction in cardiovas-
cular risk comparing allopurinol to usual therapy after
24 months of follow-up (HR 0.29, 95% CI 0.09-0.86, p =
0.026) [44]. No serious adverse events were noted in any
of the included studies, specifically allopurinol hypersen-
sitivity syndrome, toxic epidermal necrolysis or Steven-
Johnson syndrome.
Risk of bias of included studies
Overall, study quality was variable (Figure 4). The in-
ternal validity of the included RCTs was difficult to as-
sess as most studies omitted important methodological
details. Notably, some studies did not use an intention-
to-treat analysis. We were not able to report quality fea-
tures in one study as it was available in abstract form
only [34]. Although a few of the studies were not
Table 1 Study characteristics
First author (Ref No.) Year of
publication





Katholi [51] 1998 American Journal of Kidney Diseases Springfield, Illinois Parallel Group RCT with
2x2 factorial design
2 days 39 Allopurinol Placebo
Perez-Ruiz [56] 1999 Journal of Clinical Rheumatology Pais Vasco, Spain Parallel Group RCT 9-12 months 36 Benzbromarone Allopurinol
Kamper [50] 2001 Clinical Transplantation Herlev, Denmark Cross-over RCT 2 weeks 26 Losartan No treatment
Schmidt [53] 2001 Nephrology Dialysis Transplantation Vienna, Austria Cross-over RCT 3 weeks 13 Losartan Enalapril
Doehner [35] 2002 Circulation London, UK Cross-over RCT 2 weeks 14 Allopurinol Placebo
Chanard [54] 2003 Nephrology Dialysis Transplantation Three centres in France Parallel Group RCT 2 months 48 Amlodipine Tertatolol
Siu [48] 2006 American Journal of Kidney Diseases Hong Kong, China Parallel Group RCT 12 months 54 Allopurinol No treatment
Liu [36] 2007 China Pharmacy Guangzhou and Luzhou, China Parallel Group RCT 12 months 47 Allopurinol No treatment
Sarris [34] 2007 Nephrology Dialysis Transplantation Athens, Greece Parallel Group RCT 12 months 36 Allopurinol No treatment
Lei [40] 2009 Shaanxi Medical Journal Xi’an, China Parallel Group RCT 12 months 57 Allopurinol No treatment
Malaguarnera [55] 2009 Expert Opinion Pharmacotherapy Catania, Italy Parallel Group RCT 2 months 38 Rasburicase Placebo
Nouri-Majalan [52] 2009 Vascular Health and Risk
Management
Yazd, Iran Parallel Group RCT 5 days 60 Allopurinol and vitamin E No treatment
Deng [37] 2010 Journal of Practical Medicine Beijing, China Parallel Group RCT 12 months 68 Allopurinol No treatment
Goicoechea [44] 2010 Clinical Journal of American Soc of
Neph
Madrid, Spain Parallel Group RCT 24 months 113 Allopurinol No treatment
Momeni [46] 2010 Iranian Journal of Kidney Diseases Isfahan, Iran Parallel Group RCT 4 months 44 Allopurinol Placebo
Shen [38] 2010 China Foreign Medical Treatment Chengdu, China Parallel Group RCT 12 months 52 Allopurinol No treatment
Kao [45] 2011 Journal of American Soc of Neph Dundee, UK Parallel Group RCT 9 months 67 Allopurinol Placebo
Tan [39] 2011 Modern Hospital Guangzhou, China Parallel Group RCT 24 months 140 Allopurinol No treatment
















Tx age Ct age Tx gender
(F:M or % male)
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Katholi [51] sCr 1.4-2.0 mg/dl and rec contrast Excluded 60 ± 4 (NMg),
61 ± 3 (LoMg)
59 ± 5 (NMg),
63 ± 4 (LoMg)
Not reported Not reported Not reported Not reported
Perez-Ruiz [56] Chronic Gout with CrCl 20-80 Not reported 60.9 ± 12.8 67.3 ± 9.59 Not reported Not reported 9.35 ± 1.96 8.96 ± 1.84
Kamper [50] HTN CsA Renal Tr Minority M median age 47,
W median age 47
N/A 10:16 N/A 7.90 (median),
4.87-11.60 (range)
N/A
Schmidt [53] HTN CsA Renal Tr Not reported 58 ± 12 N/A 1:12 N/A 7.8 ± 2.2 7.8 ± 1.8
Doehner [35] LV dysfxn (EF < 40%), hyperUA >400 umol/L Not reported 68 ± 2 69 ± 3 100% male 100% male 8.99 ± 0.37 9.88 ± 0.62
Chanard [54] HTN CsA Renal Tr Not reported 45.2 ± 9.9 48.2 ± 11.5 7:17 8:16 8.11 ± 1.66 7.56 ± 1.65
Siu [48] sCr 120-400 umol/L Majority 47.7 ± 12.9 48.8 ± 16.8 9:4 13:15 9.75 ± 1.18 9.92 ± 1.68
Liu [36] CKD (120-400 umol/L) and hyperUA Not reported 45.6 ± 12.5 46.5 ± 13. 8 8:16 10:13 9.73 ± 0.20 9.92 ± 0.26
Sarris [34] hyperUA > 7 mg/dL, mild-mod CKD,
sCr >1.5, <3.0 mg/dL
Not reported 49.2 ± 17.3 50.4 ± 15.8 8:10 11:7 8.88 ± 1.26 9.16 ± 1.46
Lei [40] CKD with hyperUA Not reported 48.6 ± 10.2 49.5 ± 9.8 9:20 9:19 8.84 ± 1.45 8.70 ± 1.41
Malaguarnera [55] hyperUA, 65-85 yrs, sCr 2.5 mg/dl Approximately half 75.6 ± 8.4 76.4 ± 8.1 15:5 12:6 10.9 ± 2.9 10.3 ± 3.1
Nouri-Majalan [52] Pts undergoing CABG and eGFR < 60 Not reported 65 ± 9.5 61 ± 7.90 13:17 16:14 Not reported Not reported
Deng [37] CKD Not reported 60.0 ± 11.1 58.8 ± 9.4 15:14 14:18 8.59 ± 1.01 8.93 ± 0.96
Goicoechea [44] CKD Stage 3-5 Majority 72.1 ± 7.9 71.4 ± 9.5 Not reported Not reported 7.8 ± 2.1 7.3 ± 1.6
Momeni [46] T2DM Nephropathy Majority 56.3 ± 10.6 59.1 ± 10.6 11:9 11:9 5.96 ± 1.21 6.5 ± 2.2
Shen [38] CKD with hyperUA Not reported 47.1 ± 11.8 47.6 ± 12.4 8:18 9:17 9.01 ± 1.38 8.89 ± 1.50
Kao [45] LVH and CKD Stage 3 Majority 70.6 ± 6.9 73.7 ± 5.3 59% male 46% male 7.39 ± 1.5 7.06 ± 1.3
Tan [39] T2DM nephropathy eGFR, 30-60 ml/min/1.73 m2 Majority 59.3 ± 9.2 58.6 ± 8.3 35:37 33:35 8.93 ± 0.96 8.60 ± 1.01











Study name Outcome Statistics for each study Std diff in means and 95% CI
Std diff Lower Upper 
in means limit limit p-Value
Kao 2011 Proteinuria 0.211 -0.329 0.751 0.444
Momeni 2010 Proteinuria 0.731 0.091 1.371 0.025
Shi 2012 Proteinuria 0.074 -0.547 0.695 0.815
Siu 2006 Proteinuria 0.101 -0.448 0.650 0.719
Liu 2007 Proteinuria 0.155 -0.418 0.728 0.596
0.236 -0.023 0.496 0.074
-2.00 -1.00 0.00 1.00 2.00
Favours Control Favours Allopurinol
Q = 2.88; I-squared = 0.00; p = 0.579
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value
Goicoechea 2010 Serum Creatinine (mg/dL) 0.400 0.184 0.616 0.000
Momeni 2010 Serum Creatinine (mg/dL) 0.100 -0.201 0.401 0.514
Siu 2006 Serum Creatinine (mg/dL) 0.680 0.263 1.097 0.001
Sarris 2007 Serum Creatinine (mg/dL) 0.610 0.131 1.089 0.013
Lei 2009 Serum Creatinine (mg/dL) 0.701 0.369 1.032 0.000
Liu 2007 Serum Creatinine (mg/dL) 0.757 0.549 0.965 0.000
Shen 2010 Serum Creatinine (mg/dL) 0.689 0.330 1.049 0.000
Deng 2010 Serum Creatinine (mg/dL) 0.991 0.252 1.730 0.009
Tan 2011 Serum Creatinine (mg/dL) 1.182 0.678 1.685 0.000
0.629 0.433 0.825 0.000
-2.00 -1.00 0.00 1.00 2.00
Favours Control Favours Allopurinol
Q = 23.0; I-squared = 65.2; p = 0.003
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value
Goicoechea 2010 sBP 0.000 -5.583 5.583 1.000
Kao 2011 sBP 1.800 -6.142 9.742 0.657
Momeni 2010 sBP 2.200 -5.130 9.530 0.556
Siu 2006 sBP 11.000 -1.269 23.269 0.079
Lei 2009 sBP 19.000 10.211 27.789 0.000
Liu 2007 sBP 13.000 2.644 23.356 0.014
Shen 2010 sBP 16.000 6.470 25.530 0.001
Deng 2010 sBP 5.000 -1.221 11.221 0.115
Tan 2011 sBP 0.000 -4.163 4.163 1.000
6.588 2.043 11.133 0.004
-30.00 -15.00 0.00 15.00 30.00
Favours Control Favours Allopurinol
Q = 27.5; I-squared = 70.9; p = 0.001
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value
Goicoechea 2010 dBP 2.000 -1.704 5.704 0.290
Kao 2011 dBP 0.800 -3.965 5.565 0.742
Momeni 2010 dBP 2.300 -2.310 6.910 0.328
Siu 2006 dBP 4.000 -1.861 9.861 0.181
Lei 2009 dBP 2.000 -3.422 7.422 0.470
Liu 2007 dBP 5.000 -1.190 11.190 0.113
Shen 2010 dBP 2.000 -4.158 8.158 0.524
Deng 2010 dBP 5.000 -0.812 10.812 0.092
Tan 2011 dBP 0.000 -3.769 3.769 1.000
2.121 0.497 3.744 0.010
-16.00 -8.00 0.00 8.00 16.00
Favours Control Favours Allopurinol
Q = 3.69; I-squared = 0.00; p = 0.884
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value
Goicoechea 2010 Serum Uric Acid (mg/dL) 2.000 1.416 2.584 0.000
Kao 2011 Serum Uric Acid (mg/dL) 3.361 2.720 4.003 0.000
Momeni 2010 Serum Uric Acid (mg/dL) 0.590 -0.336 1.516 0.212
Shi 2012 Serum Uric Acid (mg/dL) 1.800 1.146 2.454 0.000
Siu 2006 Serum Uric Acid (mg/dL) 4.030 3.328 4.732 0.000
Sarris 2007 Serum Uric Acid (mg/dL) 4.230 3.386 5.074 0.000
Lei 2009 Serum Uric Acid (mg/dL) 2.436 1.821 3.051 0.000
Liu 2007 Serum Uric Acid (mg/dL) 4.007 3.885 4.128 0.000
Shen 2010 Serum Uric Acid (mg/dL) 2.419 1.750 3.088 0.000
Deng 2010 Serum Uric Acid (mg/dL) 2.750 2.313 3.188 0.000
Tan 2011 Serum Uric Acid (mg/dL) 3.410 3.133 3.687 0.000
2.849 2.283 3.415 0.000
-6.00 -3.00 0.00 3.00 6.00
Favours Control Favours Allopurinol
Q = 187.3; I-squared = 94.7; p = 0.000
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value
Goicoechea 2010 eGFR 5.000 2.725 7.275 0.000
Kao 2011 eGFR 0.000 -3.367 3.367 1.000
Shi 2012 eGFR 1.600 -9.263 12.463 0.773
2.581 -1.486 6.648 0.214
-16.00 -8.00 0.00 8.00 16.00
Favours Control Favours Allopurinol
Q = 5.92; I-squared = 66.2; p = 0.052
Study name Outcome Statistics for each study Difference in means and 95% CI
Difference Lower Upper 
in means limit limit p-Value
Goicoechea 2010 eGFR 5.000 2.725 7.275 0.000
Kao 2011 eGFR 0.000 -3.367 3.367 1.000
Momeni 2010 eGFR 1.650 -8.522 11.822 0.751
Shi 2012 eGFR 1.600 -9.263 12.463 0.773
Siu 2006 eGFR 7.100 -0.375 14.575 0.063
3.173 0.156 6.191 0.039
-16.00 -8.00 0.00 8.00 16.00
Favours Control Favours Allopurinol
Q =  6.95; I-squared = 42.5; p = 0.138
Figure 2 Forest plots.
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of bias per se since our outcomes of interest were
objective.Discussion
In our meta-analysis of RCTs of treatments to lower se-
rum urate, we observed a small but potentially clinically
important and statistically significant improvement in
eGFR and serum creatinine, favouring allopurinol. There
were also statistically significant reductions in systolic
and diastolic blood pressure, and serum uric acid, as ex-
pected. A tendency towards benefit for proteinuria was
shown as well.Strengths of our review include its comprehensive-
ness and robust methodology. Limitations include the
quality of our individual studies. Many of our included
trials are small, single-centre studies with relatively
short duration of follow-up. Two of our longest studies
both had no placebo arm and were open-label trials
[44,48]. Also, two of our included trials did not report
estimates of GFR; we converted serum creatinine into
eGFR values using mean demographic variables, which
is a reasonable assumption, but one which increases
measurement area for these values. We conducted a
sensitivity analysis on data that did not require these
calculations, finding a similar result but one that lacked
statistical significance.

















Funnel Plot of Standard Error by Difference in means














































































































Figure 4 Funnel plot.
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views of this question [42,41]. Bose and colleagues con-
ducted a comprehensive search of the English literature
and similarly identified the scarcity of robust data on
which to draw conclusions. Wang and colleagues
searched up to December 2011, however, they incorpo-
rated Chinese databases resulting in several non-English
RCTs. Our meta-analysis adds to these by the more re-
cent search date, including data on calculated eGFR
from studies that reported only serum creatinine as well
as reporting effects on blood pressure as an outcome.
The Cochrane Renal Group also is in the process of con-
ducting a review; their protocol is published [30].
We do not know the mechanism by which allopurinol,
or other urate-lowering therapy, is nephroprotective.
Xanthine oxidase produces reactive oxygen species
(ROS) and its inhibition with allopurinol may reduce ox-
idative stress [33]. However, it is difficult to differentiate
if such effects are secondary to the lowering of uric acid
per se or inhibition of a ROS-producing enzyme.
In rats with remnant kidneys, oxonic-acid induced hy-
peruricemia accelerates glomerulosclerosis and tubuloin-
terstitial fibrosis [57,58]. Micropuncture studies in these
same models suggest preglomerular arteriolar disease al-
ters renal autoregulation, resulting in systemic and
glomerular hypertension [59]. In all of these studies, cor-
rection of the hyperuricemic state with a uricosuric
agent can significantly improve blood pressure control,
decrease proteinuria, and slow progression of kidney dis-
ease [57,59,58]. Further studies may consider concurrently
measuring markers of oxidative stress, inflammation, and
blood pressure parameters to better understand mecha-
nisms of a potential benefit.
We also take note of the recently published long-term
follow up study of Goicoechea et al., lending further
support to treating urate in CKD. Their adjusted hazard
ratios for reduction of renal and cardiovascular events
were 0.32, with a 95% CI of 0.15-0.69, p = 0.004, and
Kanji et al. BMC Nephrology  (2015) 16:58 Page 8 of 90.43 with a 95% CI of 0.21-0.88, p = 0.02, respectively.
Notably, the definition of their renal endpoints entailed
initiation of dialysis therapy and doubling of serum cre-
atinine. However, again their data is limited by small
sample size and single-centre design. Also, as the study
was a post-hoc analysis, it did not require patients to ad-
here to previous randomly allocated treatment arms [60].
Conclusions
Though the data we summarize here are suggestive and
encouraging, using allopurinol in clinical practice to
delay progression of CKD would be premature. Given
these limitations, studies powered to measure reduction
in patient-important renal composites are necessary, and
are in progress [61-63].
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